KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to eliminate tumor cells. In the present study, we identify two TCRs specific for the 9-mer KRAS-G12V mutant neoantigen in the context of HLA-A*11:01. The TCR-T cells are constructed and display cytokine secretion and cytotoxicity upon co-culturing with varied tumor cells expressing the KRAS-G12V mutation. Moreover, 1-2C TCR-T cells show anti-tumor activity in preclinical models in female mice. The 9-mer KRAS-G12V mutant peptide exhibits a distinct conformation from the 9-mer wildtype peptide and its 10-mer counterparts. Specific recognition of the G12V mutant by TCR depends both on distinct conformation from wildtype peptide and on direct interaction with residues from TCRs. Our study reveals the mechanisms of presentation and TCR recognition of KRAS-G12V mutant peptide and describes TCRs with therapeutic potency for tumor immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570350 | PMC |
| http://dx.doi.org/10.1038/s41467-023-42010-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oncogenic KRAS mutations modulate BAX-mediated cell death.
Biochim Biophys Acta Mol Cell Res
January 2025
Centre of Molecular and Environmental Biology (CBMA), Department of Biology, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal; Institute of Science and Innovation for Bio-Sustainability (IB-S), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal. Electronic address:
Kirsten rat sarcoma viral oncogene homolog (KRAS) belongs to the GTPase RAS superfamily, which regulates several cell-signaling pathways involved in the control of important cellular functions, including apoptosis. Oncogenic mutations in KRAS are considered the most common gain-of-function mutations, affecting 30-50 % of colorectal cancer (CRC) patients. While RAS proteins usually play an anti-apoptotic role, little is known about the involvement of KRAS mutations in apoptosis regulation.
View Article and Find Full Text PDFTreatment with T cells genetically engineered to express tumor-reactive T cell receptors (TCRs), known as TCR-gene therapy (TCR-T), is a promising immunotherapeutic approach for patients with cancer. The identification of optimal TCRs to use and tumor antigens to target are key considerations for TCR-T. In this issue of the JCI, Bear and colleagues report on their use of in vitro assays to characterize four HLA-A*03:01- or HLA-A*11:01-restricted TCRs targeting the oncogenic KRAS G12V mutation.
View Article and Find Full Text PDFMutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy.
Ann Surg
October 2024
Northwestern Quality Improvement, Research & Education in Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL.
Article Synopsis
- The study aimed to assess the prognostic significance of circulating tumor DNA (ctDNA) in patients with localized pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemotherapy (NAC) using a specific testing method called digital droplet PCR (ddPCR).
- Researchers enrolled 84 patients and found that mutant KRAS ctDNA was present in a significant percentage of patients at various treatment stages, with clearance of ctDNA during NAC linked to better overall survival (OS).
- The presence of the KRAS G12V mutation after surgery was strongly associated with poorer survival outcomes, indicating its potential as a negative prognostic marker in this patient group.
Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation.
Am J Cancer Res
September 2024
Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University Providence, RI 02903, USA.
Article Synopsis
- KRAS mutations are prevalent in metastatic colorectal cancer (mCRC) and pancreatic cancer, leading to treatment resistance, particularly against anti-EGFR therapies.
- Recent studies demonstrated that the drug MRTX1133, a selective inhibitor of KRAS G12D, shows strong preclinical effectiveness when combined with other cancer treatments like 5-Fluorouracil (5-FU) or ONC212 in fighting mCRC and pancreatic cancer cell lines.
- The research suggests that combinations of MRTX1133 with 5-FU or ONC212 can enhance anti-cancer activity, warranting further investigation into their use against other KRAS mutations, particularly G12V and G13D, in clinical trials.
Article Synopsis
- ADT-1004 is a new oral prodrug that effectively inhibits tumor growth and RAS activation in pancreatic ductal adenocarcinoma (PDAC) models without causing significant toxicity.
- It works by blocking ERK phosphorylation in tumor cells, showing effectiveness against various KRAS mutations and increasing immune cell presence in the tumor microenvironment.
- ADT-1004’s broad antitumor activity and selectivity for KRAS mutant tumors make it a promising candidate for clinical trials in treating PDAC, potentially outperforming existing KRAS inhibitors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!